Lymphoma, Mantle-Cell
-
Subject Areas on Research
- Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.
- Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
- B-cell lymphoma with hyaline vascular Castleman disease-like features: a clinicopathologic study.
- Bilateral panocular involvement with mantle-cell lymphoma.
- CD52 expression in mantle cell lymphoma.
- Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.
- Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.
- Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.
- Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
- Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.
- Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
- Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.
- Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.
- Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
- Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.
- Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
- SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.
- Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
- Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma.
- Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen.
- Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
- The biology of human lymphoid malignancies revealed by gene expression profiling.
- The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.
- Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
- Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.
- Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma.
-
Keywords of People
- Stefanovic, Alexandra, Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy